CoChat
Sign Up
Cited by 63Probiotics and Fermented FoodsNeonatal and Maternal InfectionsInfant Nutrition and Health

Sever Sepsis After Probiotic Treatment With Escherichia coli NISSLE 1917

Guenther, Katrin, Straube, Eberhardt, Pfister, Wolfgang, Guenther, Albrecht, Huebler, Axel·2010·Pediatric Infectious Disease Journal
DOI 10.1097/inf.0b013e3181c36eb9
Open this paper in CoChat — free account

Abstract

To the Editors: We report a case of an eutrophic preterm infant with a gestational age of 28 weeks and a birth weight of 935 g. The early postnatal phase was uncomplicated. On postnatal day 13, the infant developed gastroenteritis due to a rotavirus and adenovirus coinfection. A blood culture had no growth. To facilitate the physiologic intestinal bacterial flora on day 15 of life, we initiated a probiotic treatment with Escherichia coli NISSLE 1917 in the recommended dosage for this age group (1 mL once a day), with an immediate positive effect on the oral feeding. On postnatal day 25, a dramatic deterioration occurred with the infant showing a sepsis syndrome with fever, apnea attacks and hypotension. Blood cultures yielded E. coli, which was showing pulsed field gelelectrophoresis to be E. coli Nissle 1917 with clonal identity to the strain used therapeutically (Fig. 1). After intensified therapy with vasopressors, antibiotic treatment active against the isolated strain (meropenem in combination with vancomycine because of the central venous catheter), and intravenous immunoglobulins the patient stabilized and at 10 weeks of age was discharged in good clinical condition.FIGURE 1.: Result of the pulsed field gel electrophoresis. Lane 1: E. coli strain NISSLE 1917. Lane 2: E. coli strain isolated of the blood culture.Colonization with potentially pathogenic Gram negative bacteria is a risk factor for the development of necrotizing enterocolitis. Therefore, probiotics as live microbial supplements in preterms are used with the objective to support the intestinal colonization as well as to prevent infections or side effects of antibiotic drugs.1 It is unknown whether probiotic treatment increases or decreases the risk of invasive infection in preterm infants weighing less than 1500 g. The safety of this therapy is uncertain. Because of the immaturity of the gastrointestinal tract and of the local and systemic immune system in preterm infants the risk of systemic infections is increased. In a small study with 27 healthy newborns, E. coli strain NISSLE 1917 colonized the intestines within a few days and was well tolerated.2 Despite the fact that many studies have shown that E. coli NISSLE can replace pathogenic bacteria in the intestinal flora by means of intensive adherence to epithelial cells, analysis of the genomic structure has revealed a potential pathogenicity.3 Sepsis associated with probiotic supplementation in preterm infants with a very low birth weight (<1500 g) has not been previously reported. The immaturity of the immune system as well as the gastrointestinal tract combined with an increased permeability of the intestinal wall related to infection with rotavirus and adenovirus resulting in translocation of bacteria from the mucous membranes to the blood stream. After the neonatal period the probiotic prophylaxis is associated with an increased risk of sepsis in patients with severe acute pancreatitis and AIDS.4,5 In infancy, only a few case reports exist describing sepsis or meningitis complicated by Lactobacillus GG and Saccharomyces cerevisiae independent of probiotic supplementation.6,7 All cases of sepsis related to probiotics have occurred in patients with underlying immune compromise or chronic disease. Many case reports of probiotic sepsis describe patients with preexisting intestinal pathology, a common indication for probiotic use, but also associated with an increased risk of probiotic translocation from the intestinal mucosa. The presence of a central venous catheter is also a frequent finding and is considered as a possible source of sepsis. Studies with athymic neonatal mice have shown that the colonization with probiotics can lead to increased mortality.8 This finding suggests that the immaturity of the immune system in preterm infants put them at particularly high risk for probiotic-associated sepsis. The present case report should prompt a discussion of pros and cons of probiotic use. Additional systematical investigations and well organized clinical studies are needed to clarify risk factors for the development of septic complications after a treatment with probiotics. Katrin Guenther, MD Eberhardt Straube, MD Wolfgang Pfister, MD Albrecht Guenther, MD Axel Huebler, MD Department of Pediatrics Friedrich-Schiller University Jena, Germany

Integrity signals

Registry

Crossref · 10.1097/inf.0b013e3181c36eb9

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Adverse events from probiotic strains in vulnerable populations include life-threatening pneumonia, endocarditis, and sepsis.

    “AEs include life-threatening pneumonia,106 endocarditis,107–111 and sepsis.112–115”

    From Emerging issues in probiotic safety: 2023 perspectives (2023) · cites this paper as [113]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Guenther, K., Straube, E., Pfister, W., Guenther, A., & Huebler, A.
Venue
Pediatric Infectious Disease Journal
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2010-02
Volume
29
Issue
2
Pages
188-189
ISSN
0891-3668 (ISSN-L)
DOI
10.1097/inf.0b013e3181c36eb9
OpenAlex
W2000754880
Cited by
63
References
8
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 8 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 6 · 2014: 5 · 2013: 4 · 2012: 6
FWCI
8.35
Type
journal article
Language
en
Open access
closed
Locations
  • The Pediatric Infectious Disease Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Neonatal and Maternal Infections
  • Health Sciences › Nursing › Nutrition and Dietetics › Infant Nutrition and Health
Keywords
Escherichia coli Nissle 1917, probiotics, sepsis, preterm infants, neonatal sepsis, probiotic safety, rotavirus gastroenteritis, intestinal colonization, pulsed-field gel electrophoresis, central venous catheters
MeSH terms
Anti-Bacterial Agents, Blood, Escherichia coli, Escherichia coli Infections, Genotype, Humans, Infant, Newborn, Bacterial Typing Techniques, DNA Fingerprinting, Electrophoresis, Gel, Pulsed-Field, Sepsis, Probiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review